{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:59:14Z","timestamp":1793386754801,"version":"4.5.0"},"reference-count":15,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6,13]]},"DOI":"10.1182\/bloodadvances.2022008643","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T14:44:06Z","timestamp":1662734646000},"page":"2575-2579","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["Racial and socioeconomic disparities in CLL\/SLL: analysis of SEER data from 2006 to 2019"],"prefix":"10.1182","volume":"7","author":[{"given":"Adam S.","family":"Kittai","sequence":"first","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Huang","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema A.","family":"Bhat","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Electra D.","family":"Paskett","sequence":"additional","affiliation":[{"name":"2Division of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH"},{"name":"3The Center for Cancer Health Equity, The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5748-7874","authenticated-orcid":false,"given":"Kerry A.","family":"Rogers","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline C.","family":"Barrientos","sequence":"additional","affiliation":[{"name":"4Mount Sinai Medical Center Comprehensive Cancer Center, Miami Beach, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3211-2691","authenticated-orcid":false,"given":"James L.","family":"Fisher","sequence":"additional","affiliation":[{"name":"5James Cancer Hospital and Solove Research Institute, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Woyach","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,6,2]]},"reference":[{"issue":"23","key":"2023061216332357900_bib1","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"10232","key":"2023061216332357900_bib2","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"26","key":"2023061216332357900_bib3","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2023061216332357900_bib4","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib\u2013rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2023061216332357900_bib5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clml.2019.09.625","article-title":"Randomized clinical trial representativeness and outcomes in real-world patients: comparison of 6 hallmark randomized clinical trials of relapsed\/refractory multiple\u00a0myeloma","volume":"20","author":"Chari","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"2023061216332357900_bib6","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1080\/03007995.2021.1929894","article-title":"Real-world treatment sequencing and healthcare costs among CLL\/SLL patients treated\u00a0with venetoclax","volume":"37","author":"Rogers","year":"2021","journal-title":"Curr Med Res Opin"},{"issue":"17","key":"2023061216332357900_bib7","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/blood.2020004922","article-title":"Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia","volume":"136","author":"Patel","year":"2020","journal-title":"Blood"},{"issue":"9","key":"2023061216332357900_bib8","doi-asserted-by":"crossref","DOI":"10.1097\/MLR.0b013e31829faffd","article-title":"Cancer patients' trade-offs among efficacy, toxicity and out-of-pocket cost in the curative and non-curative setting","volume":"51","author":"Wong","year":"2013","journal-title":"Med Care"},{"issue":"11","key":"2023061216332357900_bib9","first-page":"1468","article-title":"Racial disparities in medication use: imperatives for managed care pharmacy","volume":"26","author":"Kogut","year":"2020","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"1","key":"2023061216332357900_bib10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10552-013-0310-1","article-title":"Using a composite index of socioeconomic status to investigate health disparities while protecting the confidentiality of cancer registry data","volume":"25","author":"Yu","year":"2014","journal-title":"Cancer Causes Control"},{"issue":"12","key":"2023061216332357900_bib11","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.3109\/10428194.2014.898758","article-title":"The impact of race, ethnicity, age and sex on clinical outcome in chronic lymphocytic leukemia: a comprehensive Surveillance, Epidemiology, and End Results analysis in the modern era","volume":"55","author":"Nabhan","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2023061216332357900_bib12","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/bloodadvances.2019001145","article-title":"The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites","volume":"4","author":"Mato","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"2023061216332357900_bib13","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.clml.2011.07.002","article-title":"Racial differences in the presentation and outcomes of chronic lymphocytic leukemia and variants in the United States","volume":"11","author":"Shenoy","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"17","key":"2023061216332357900_bib14","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1002\/cncr.28030","article-title":"Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic leukemia: joint experience of the MD Anderson Cancer Center and Duke University Medical Center","volume":"119","author":"Falchi","year":"2013","journal-title":"Cancer"},{"issue":"7","key":"2023061216332357900_bib15","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/ajh.24374","article-title":"Analysis of racial variations in disease characteristics, treatment patterns, and outcomes of patients with chronic lymphocytic leukemia","volume":"91","author":"Nabhan","year":"2016","journal-title":"Am J Hematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/11\/2575\/2056773\/blooda_adv-2022-008643-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/11\/2575\/2056773\/blooda_adv-2022-008643-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T16:34:27Z","timestamp":1686587667000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/11\/2575\/486560\/Racial-and-socioeconomic-disparities-in-CLL-SLL"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,2]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,6,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022008643","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,2]]}}}